PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	~~Unassigned~~ Reitsang Shiao
Attorney Docket Number	021305-003900US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,855,695	02-15-2005	Xu et al.	
	AB	US-6,656,926	12-02-2003	Borch et al.	
	AC	US-6,251,933	06-26-2001	Denny et al.	
	AD	US-6,130,237	10-10-2000	Denny et al.	
	AE	US-6,020,315	02-01-2000	Bosslet et al.	
	AF	US-5,985,909	11-16-1999	Denny et al.	
	AG	US-5,877,158	03-02-1999	Bosslet et al.	
	AH	US-5,872,129	02-16-1999	Denny et al.	
	A1	US-5,780,585	07-14-1998	Anlezark et al.	
	AJ	US-5,750,782	05-12-1998	Denny et al.	
	AK	US-5,703,080	12-30-1997	Nakakura et al.	
	AL	US-5,622,936	04-22-1997	Wiessler et al.	
	AM	US-5,472,956	12-05-1995	Borch et al.	
	AN	US-5,403,932	04-04-1995	Borch et al.	
	AO	US-5,306,727	04-26-1994	Borch et al.	
	AP	US-5,190,929	03-02-1993	Borch et al.	
	AQ	US-4,921,963	05-01-1990	Skov et al.	
	AR	US-4,908,356	03-13-1990	Borch et al.	
	AS	US-3,652,579	03-28-1972	Hoffer et al.	
	AT	US-2005/0043244 A1	02-24-2005	Lin et al.	
	AU	US-2004/0254103 A1	12-03-2004	Xu et al.	
	AV	US-2004/0176332 A1	09-09-2004	Borch et al.	
	AW	US-2004/0121940 A1	06-24-2004	De Groot et al.	
	AX	US-2003/0130189 A1	07-10-2003	Sender et al.	
	AY	US-2003/0096743 A1	05-22-2003	Sender et al.	
	AZ	US-2003/0050331 A1	03-13-2003	Ng et al.	
	BA	US-2003/0008850 A1	01-09-2003	Borch et al.	

Examiner Signature	/Rei Tsang Shiao/ (07/21/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

	Complete if Known
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	~~Unassigned~~ Reitsang Shiao
Attorney Docket Number	021305-003900US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (if known)				
	BB	DE	2229223		02-15-1973			☐
	BC	EP	648 503	A1	04-19-1995			☐
	BD	WO	04/85421	A2	10-07-2004			☐
	BE	WO	04/85361	A1	10-07-2004			☐
	BF	WO	02/96910	A1	12-05-2002			☐
	BG	WO	00/64864	A1	11-02-2000			☐

Examiner Signature	/Rei Tsang Shiao/ (07/21/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols (if known). [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (07-06)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

	Complete if Known
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	~~Unassigned~~ Reitsang Shiao
Attorney Docket Number	021305-003900US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BH	BERRY et al., "5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated pro-drug system," J. Chem. Soc. Perkin Trans., 1:1147-1156 (1997).	☐
	BI	BORCH et al., "Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents," J. Med. Chem., 43:2258-2265 (2000).	☐
	BJ	BORCH et al., "Antitumor Activity and Toxicity of Novel Nitroheterocylic Phosphoramidates," J. Med. Chem., 44:74-77 (2001).	☐
	BK	DE GROOT et al., "Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors," Current Medical Chemistry, 8:1093-1122 (2001).	☐
	BL	DE JAEGER et al., "Relationship of hypoxia to metastatic ability in rodent tumours," Br. J. Cancer, 84(9):1280-1285 (2001).	☐
	BM	ENGLE et al., "^{31}P NMR Kinetic Studies of the Intra- and Intermolecular Alkylation Chemistry of Phosphoramide Mustard and Cognate N-Phosphorylated Derivatives of *N ,N* -Bis(2-chloroethyl)amine[1,]," J. Med. Chem., 25:1347-1357 (1982).	☐
	BN	EVERETT et al., "Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release," Biochemical Pharmacology, 63:1629-1639 (2002).	☐
	BO	EVERETT et al., "Bioreductively-Activated Prodrugs for Targeting Hypoxic Tissues: Elimination of Aspirin from 2-Nitroimidazole Derivatives," Biooganic Med. & Chem. Ltrs., 9:1267-1272 (1999).	☐
	BP	HAY et al., "A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL)Carbonyl]-1,2-Dihydro-3*H*-Benz[E]Indole (Amino-*Seco*- CBI-TMI) for Use With Adept and Gdept," Biooganic Med. & Chem. Ltrs., 9:2237-2242 (1999).	☐
	BQ	HAY et al., "Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine," J. Med. Chem., 46:169-182 (2003).	☐
	BR	HERNICK et al., "Design, Synthesis, and Biological Evaluation of Indolequinone Phosphoramidate Prodrugs Targeted to DT-diaphorase," J. Med. Chem., 45:3540-3548 (2002).	☐
	BS	HERNICK et al., "Studies on the Mechanisms of Activation of Indolequinone Phosphoramidate Prodrugs," J. Med. Chem., 46:148-154 (2003).	☐

Examiner Signature	/Rei Tsang Shiao/ (07/21/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

60917705 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RS/

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/549,545
Filing Date	May 26, 2006
First Named Inventor	Matteucci, Mark
Art Unit	1626
Examiner Name	~~Unassigned~~ Reitsang Shiao
Attorney Docket Number	021305-003900US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BT	KYLE et al., "Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture," Cancer Research, 64:6304-6309 (2004).	☐
	BU	LIN et al., "(*o*- and *p*- Nitrobenzyloxycarbobyl) -5-fluorouracil Derivatives as Potential Conjugated Bioreductive Alkylating Agents," J. Med. Chem., 29:84-89 (1986).	☐
	BV	NAYLOR et al., "Recent Advances in Bioreductive Drug Targeting," Mini Reviews in Med. Chem., 1:17-29 (2001).	☐
	BW	PAPOT et al., "Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies," Curr. Med. Chem. - Anti-Cancer Agents, 2:155-185 (2002).	☐
	BX	PARVEEN et al., "2-Nitroimidazol-5-Ylmethyl as a Potential Bioreductively Activated Prodrug System: Reductively Triggered Release of the Parp Inhibitor 5-Bromoisoquinolinone," Bioganic Med. & Chem. Ltrs., 9:2031-2036 (1999).	☐
	BY	ROFSTAD et al., "Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis," Br. J. Cancer, 80(11):1697-1707 (1999).	☐
	BZ	ROSEN et al., "Phase I Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies," Clin. Cancer Res., 10:3689-3698 (2004).	☐
	CA	STEINBERG et al., "Synthesis and Evaluation of Pteroic Acid-Conjugated Nitroheterocyclic Phosphoramidates as Folate Receptor - Targeted Alkylating Agents," J. Med. Chem., 44:69-73 (2001).	☐
	CB	WAKSELMAN, M., "1,4- and 1,6- Eliminations from Hydroxy- and Amino-Substituted Benzyl Systems: Chemical and Biochemical Applications," Nouv. J. Chim., 7(7):439-447 (1983).	☐
	CC	WEST et al., "A comparison of adriamycin and mAMSA, II. Studies with V79 and human tumour multicellular spheroids," Cancer Chemother. Pharmacol., 20:109-114 (1987).	☐
	CD	WORKMAN et al., "The experimental development of bioreductive drugs and their role in cancer therapy," Cancer and Metastasis Rev., 12:73-82 (1993).	☐

Examiner Signature	/Rei Tsang Shiao/ (07/21/2008)	Date Considered	

[1]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

60917705 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RS/